{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:42:44Z","timestamp":1791679364485,"version":"4.3.4"},"reference-count":33,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia and sickle cell disease. However, shadowing the excitement about the transformational potential of many gene therapies has been widespread concern about the combination of uncertainty in the durability of their benefits over the long term and the short-term financial shock of high prices. As the healthcare payment ecosystem prepares for the growing number of gene therapies entering the market, three key interconnected challenges must be addressed: determining a fair price, managing clinical uncertainty and managing short-term budget impacts. This paper identifies specific policy reforms and market-based tools to help the US health system address these challenges to achieve more equitable and affordable access for patients to the growing number of gene therapies expected to be approved in the coming years.<\/jats:p>","DOI":"10.57264\/cer-2024-0118","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:56:21Z","timestamp":1731567381000},"source":"Crossref","is-referenced-by-count":39,"title":["Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States"],"prefix":"10.57264","volume":"13","author":[{"given":"Sharon","family":"Phares","sequence":"first","affiliation":[{"name":"NEWDIGS, Tufts Center for Biomedical System Design, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Trusheim","sequence":"additional","affiliation":[{"name":"NEWDIGS, Tufts Center for Biomedical System Design, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K","family":"Emond","sequence":"additional","affiliation":[{"name":"Institute for Clinical &amp; Economic Review, MA 02108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Pearson","sequence":"additional","affiliation":[{"name":"Institute for Clinical &amp; Economic Review, MA 02108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_2_2","unstructured":"Paying for Cures NEWDIGS Tufts Medical Center website. Approved cell and gene therapy (CGT) products. (2023). https:\/\/newdigs.tuftsmedicalcenter.org\/payingforcures\/defining-disruption\/cell-and-gene-therapy-products-and-pipeline\/approved-cell-and-gene-therapy-products\/"},{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/d41586-022-04327-7","article-title":"Researchers welcome $3.5-million haemophilia gene therapy \u2013 but questions remain","volume":"612","author":"Naddaf M","year":"2022","unstructured":"Naddaf M. Researchers welcome $3.5-million haemophilia gene therapy \u2013 but questions remain. Nature 612, 388\u2013389 (2022). https:\/\/www.nature.com\/articles\/d41586-022-04327-7","journal-title":"Nature"},{"key":"e_1_3_8_4_2","unstructured":"Paying for Cures NEWDIGS Tufts Medical Center website. Cell and Gene Therapy (CGT) pipeline deep dive. (2023). https:\/\/newdigs.tuftsmedicalcenter.org\/payingforcures\/defining-disruption\/cell-and-gene-therapy-products-and-pipeline\/cgt-pipeline-deep-dive\/"},{"key":"e_1_3_8_5_2","article-title":"Gene Therapy Drugs That Cost Millions Have Employers and Health Plans Worried","author":"Tozzi J","year":"2019","unstructured":"Tozzi J. Gene Therapy Drugs That Cost Millions Have Employers and Health Plans Worried. Insurance Journal.com (2019). https:\/\/www.insurancejournal.com\/news\/national\/2019\/09\/13\/539591.htm","journal-title":"Insurance Journal.com"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00527"},{"key":"e_1_3_8_7_2","unstructured":"Midwest Business Group on Health (MBGH). 2023 Employer Health Benefits Priorities. (2023). https:\/\/higherlogicdownload.s3.amazonaws.com\/MBGH\/ef998dc2-0de9-4904-b6d7-a36b4c0cef4b\/UploadedImages\/Benchmarking\/2022\/MBGH_Annual_Survey_Infographic-Final.pdf"},{"key":"e_1_3_8_8_2","article-title":"The rise of expensive gene therapies could cure disease \u2013 and bankrupt employers","author":"Walsh D","year":"2023","unstructured":"Walsh D. The rise of expensive gene therapies could cure disease \u2013 and bankrupt employers. Crains Detroit Business (2023). https:\/\/www.crainsdetroit.com\/health-care\/new-gene-therapies-could-put-cost-pressures-employers","journal-title":"Crains Detroit Business"},{"key":"e_1_3_8_9_2","article-title":"Assessing CMMI's proposals on Medicaid payment for cell and gene therapies","author":"Fiedler M","year":"2024","unstructured":"Fiedler M, Frank RG. Assessing CMMI's proposals on Medicaid payment for cell and gene therapies. Brookings (2024). https:\/\/www.brookings.edu\/articles\/assessing-cmmis-proposals-on-medicaid-payment-for-cell-and-gene-therapies\/","journal-title":"Brookings"},{"key":"e_1_3_8_10_2","unstructured":"Paying for Cures NEWDIGS Tufts Medical Center website. (2023). https:\/\/newdigs.tuftsmedicalcenter.org\/payingforcures\/"},{"key":"e_1_3_8_11_2","unstructured":"Institute for Clinical and Economic Review. Value Assessment Methods and Pricing Recommendations for Potential Cures: A Technical Brief. (2019). https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/Valuing-a-Cure-Technical-Brief.pdf"},{"issue":"5","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: no easy answers","volume":"21","author":"Ollendorf DA","year":"2018","unstructured":"Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health 21(5), 547\u2013552 (2018).","journal-title":"Value Health"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0184"},{"key":"e_1_3_8_14_2","article-title":"Medicaid \u2018best price\u2019 approach to drug costs needs an upgrade","author":"White J","year":"2017","unstructured":"White J. Medicaid \u2018best price\u2019 approach to drug costs needs an upgrade. STAT (2017). https:\/\/www.statnews.com\/2017\/11\/10\/drug-pricing-medicaid-value-based\/","journal-title":"STAT"},{"issue":"5","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1215\/03616878-4249796","article-title":"Innovative contracting for pharmaceuticals and Medicaid's best-price rule","volume":"43","author":"Sachs R","year":"2018","unstructured":"Sachs R, Bagley N, Lakdawalla DN. Innovative contracting for pharmaceuticals and Medicaid's best-price rule. Health Polit Policy Law 43(5), 5\u201318 (2018).","journal-title":"Health Polit Policy Law"},{"key":"e_1_3_8_16_2","unstructured":"NEWDIGS FoCUS. Payer perspectives on outcomes tracking for value-based payment arrangement (VBPs) [research brief]. (2021). https:\/\/newdigs.tuftsmedicalcenter.org\/wp-content\/uploads\/2022\/06\/FoCUS-Research-Brief-Outcomes-Tracking-2021F203v053.pdf"},{"key":"e_1_3_8_17_2","unstructured":"bluebirdbio. bluebird bio Details Plans for the Commercial Launch of LYFGNIA\u00ae Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events. (2023). https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-details-plans-commercial-launch-lyfgeniatm-gene"},{"key":"e_1_3_8_18_2","unstructured":"NEWDIGS FoCUS. Emerging market solutions for financing and reimbursement of durable cell and gene therapies (white paper). (2021). https:\/\/newdigs.tuftsmedicalcenter.org\/wp-content\/uploads\/2022\/06\/FoCUS-WP-GENETHERAPY-Market-Solutions.pdf"},{"key":"e_1_3_8_19_2","unstructured":"NEWDIGS. Multi-year milestone-based contracts. (2023). https:\/\/newdigs.tuftsmedicalcenter.org\/payingforcures\/financing-therapies\/precision-financing-solutions\/multiyear-milestone-based-contracts\/"},{"key":"e_1_3_8_20_2","unstructured":"Biomarin. Press Release. US Food and Drug Administration Approves BioMarin's ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) the First and Only Gene Therapy for Adults with Severe Hemophilia A. (2024). https:\/\/investors.biomarin.com\/news\/news-details\/2023\/U.S.-Food-and-Drug-Administration-Approves-BioMarins-ROCTAVIAN-valoctocogene-roxaparvovec-rvox-the-First-and-Only-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A-06-29-2023\/default.aspx"},{"key":"e_1_3_8_21_2","unstructured":"Paying for Cures NEWDIGS Tufts Medical Center website. (2023). https:\/\/qrco.de\/precisionFinancingWarranty"},{"key":"e_1_3_8_22_2","unstructured":"InsuranceBusiness.com. Marsh Octaviant partner on warranty program for advanced therapies. (2023). https:\/\/www.insurancebusinessmag.com\/us\/news\/life-insurance\/marsh-octaviant-partner-on-warranty-program-for-advanced-therapies-445333.aspx"},{"key":"e_1_3_8_23_2","unstructured":"CareMetx\u00ae. CGENE THERAPY Solutions Acquired OutcomeRx to Advance Next Generation Reinsurance and Warranty Products. (2023). https:\/\/caremetx.com\/cgene therapy-solutions-acquires-outcomerx-to-advance-next-generation-reinsurance-and-warranty-products\/"},{"key":"e_1_3_8_24_2","article-title":"How does Pfizer's new warranty program for XALKORI get around Medicaid Best Price?","author":"Foley Hoag","year":"2021","unstructured":"Foley Hoag. How does Pfizer's new warranty program for XALKORI get around Medicaid Best Price? JDSupra (2021). https:\/\/www.jdsupra.com\/legalnews\/how-does-pfizer-s-new-warranty-program-8274851\/","journal-title":"JDSupra"},{"issue":"6","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jval.2018.12.004","article-title":"Are payers ready, willing, and able to provide access to new durable gene therapies?","volume":"22","author":"Barlow J","year":"2019","unstructured":"Barlow J, Yang M, Teagarden JR. Are payers ready, willing, and able to provide access to new durable gene therapies? Value Health 22(6), 642\u2013647 (2019).","journal-title":"Value Health"},{"key":"e_1_3_8_26_2","unstructured":"NEWDIGS FoCUS. Precision Financing Solutions for Durable \/ Potentially Curative Therapies. (2019). https:\/\/newdigs.tuftsmedicalcenter.org\/wp-content\/uploads\/2019\/02\/MIT-FoCUS-Precision-Financing-2019F201v023.pdf"},{"key":"e_1_3_8_27_2","unstructured":"NEWDIGS FoCUS. The Role of Stop-Loss Insurance and Reinsurance in Managing Performance-Based Agreements (white paper). (2023). https:\/\/newdigs.tuftsmedicalcenter.org\/the-role-of-stop-loss-insurance-and-reinsurance-in-managing-performance-based-agreements\/"},{"key":"e_1_3_8_28_2","unstructured":"Kaiser Family Foundation. 2022 Employer Health Benefits Survey. Section 10: Plan Funding. (2023). https:\/\/www.kff.org\/report-section\/ehbs-2022-section-10-plan-funding\/"},{"issue":"3","key":"e_1_3_8_29_2","first-page":"SP1,SP112","article-title":"The impact of reinsurance of gene therapies on employer financial risk","volume":"27","author":"Hixson M","year":"2021","unstructured":"Hixson M, Minkoff NB, Gwiazdzinski K, Clement J. The impact of reinsurance of gene therapies on employer financial risk. AJMC Evidence-Based Oncology 27(3), SP1,SP112\u2013SP115 (2021). https:\/\/www.ajmc.com\/view\/the-impact-of-reinsurance-of-gene-therapies-on-employer-financial-risk","journal-title":"AJMC Evidence-Based Oncology"},{"key":"e_1_3_8_30_2","unstructured":"Bachler R Jackson A Naber J Runyan B. Managing risks related to gene and cell therapies for self-insured employers with stop-loss coverage. (2020). https:\/\/www.milliman.com\/-\/media\/milliman\/pdfs\/articles\/managing_risks_related_to_gene_and_cell_therapies_for_self-insured_employers_with_stop-loss-coverage.ashx"},{"issue":"19","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment \u2013 the \u201cNetflix model\u201d","volume":"320","author":"Trusheim MR","year":"2018","unstructured":"Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis C treatment \u2013 the \u201cNetflix model\u201d. JAMA 320(19), 1977\u20131978 (2018).","journal-title":"JAMA"},{"key":"e_1_3_8_32_2","unstructured":"Centers for Medicare & Medicaid Services. Cell and Gene Therapy (CGT) Access Model. (2024). https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/cgt"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00527"},{"key":"e_1_3_8_34_2","unstructured":"Medicaid.gov. State Plan Amendments (SPA) US Map Identifying States with VBP SRAs and Original Effective Dates. (2023). https:\/\/www.medicaid.gov\/sites\/default\/files\/2023-09\/medicaid-pharmacy-value-based-purchasing-09122023.pdf"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:59:02Z","timestamp":1732777142000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.57264\/cer-2024-0118"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0118","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"article-number":"e240118"}}